A number of other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Chardan Capital reissued a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Roth Capital raised their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Finally, Goldman Sachs Group lifted their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $69.54.
Shares of CRSP opened at $72.37 on Friday. The stock has a market capitalization of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The company’s fifty day moving average is $54.81 and its two-hundred day moving average is $47.38.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its position in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after purchasing an additional 986 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new position in shares of Crispr Therapeutics in the second quarter valued at $41,000. ARK Investment Management LLC raised its stake in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the last quarter. Finally, Aperio Group LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth $153,000. 49.81% of the stock is owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Liquidity
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.